China-based Fangzhou Inc., a leader in internet healthcare solutions, has signed a Memorandum of Understanding (MoU) with Novo Nordisk, a leading global healthcare company. Leveraging its artificial intelligence (AI) application services, innovative treatment solutions, and convenient pharmaceutical services, Fangzhou will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity.
By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector.
The aim is to shift the focus from a "disease-centered" approach to a "health-centered" model, providing patients with higher quality and more convenient one-stop healthcare services.
Fangzhou’s founder, chairman, and CEO Dr Xie Fangmin remarked, "We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale."
Christine Zhou, Novo Nordisk Senior Vice President & President of Region China said, "With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments."
Looking forward, both companies expect to explore further innovative collaborations in the medical industry's digital transformation, with the goal of benefiting patients with serious chronic diseases and accelerating the achievement of the "Healthy China 2030" strategic objectives.
